Literature DB >> 9364204

Intratumoral differences in methotrexate levels within human osteosarcoma xenografts studied by microdialysis.

P O Ekstrøm1, K E Giercksky, A Andersen, O S Bruland, L Slørdal.   

Abstract

A central tenet in oncology is the assumed relationship between drug concentration and cytotoxicity. Determinations of drug levels in tumor tissues are, however, generally not undertaken. Microdialysis is a method where continuous drug monitoring may be achieved by sampling of low molecular weight substances from the extracellular space. By employing this technique it is possible to observe variable drug levels within tissues, including tumors, over time. Herein, we present results from a nude rat model where subcutaneous human osteosarcoma xenografts were established prior to the administration of the antifolate methotrexate as an intravenous infusion. Significant differences in drug exposure within single tumors were evident. Generally, peak drug concentrations were lower and drug efflux slower from the center of the tumors as compared to the periphery. The use of microdialysis could be an important tool for optimizing current strategies in anticancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9364204     DOI: 10.1016/s0024-3205(97)00839-4

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

Review 1.  Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future.

Authors:  Christian Joukhadar; Markus Müller
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Rat models of bone metastases.

Authors:  Stéphane Blouin; Michel Félix Baslé; Daniel Chappard
Journal:  Clin Exp Metastasis       Date:  2006-05-03       Impact factor: 5.150

3.  Population Pharmacokinetic Modeling of Etoposide Free Concentrations in Solid Tumor.

Authors:  Maiara Cássia Pigatto; Bibiana Verlindo de Araujo; Bruna Gaelzer Silva Torres; Stephan Schmidt; Paolo Magni; Teresa Dalla Costa
Journal:  Pharm Res       Date:  2016-04-11       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.